Norovirus vaccine reduces symptoms of illness by more than half, early research shows

An investigational vaccine appears generally well tolerated and effective against the most common strain of norovirus, reducing the main symptoms of the gastrointestinal (GI) infection, vomiting and/or diarrhea, by 52 percent, suggests research being presented at IDWeek 2013.

Currently, there is no treatment or cure for norovirus, the most common cause of severe GI infection in the United States. Norovirus is highly contagious. Significant outbreaks occur in health care facilities, childcare centers and other places where people are in close quarters, including in the military and on cruise ships. Each year, 19 to 21 million Americans – one in 15 – are infected and as many as 800 die, according to the Centers for Disease Control and Prevention (CDC). In addition, one recent evaluation reports that the overall cost of the disease in the United States is $5.5 billion annually.

"Norovirus truly is a global issue and most if not everyone has experienced it to some degree," said David I. Bernstein, MD, MA, professor of pediatrics at Cincinnati Children's Hospital Medical Center and the University of Cincinnati and lead author of the study. "The results of our study are promising and our next step is to test this vaccine in a real-world setting."

The randomized, multi-center study included 98 people who agreed to drink water containing a significant dose of the virus, 50 who received the injected vaccine and 48 who received a placebo injection that did not contain the vaccine. Neither the participants nor the researchers knew in advance who received the vaccine and who did not. In the vaccine group, 26 (52 percent) were infected, as were 29 (60 percent) of those in the non-vaccine group. In people who received the vaccine, 10 (20 percent) suffered from mild, moderate or severe vomiting and/or diarrhea versus 20 (42 percent) in the non-vaccine group, a 52 percent reduction in symptoms.

The vaccine targets two genotypes of norovirus: GI.1 and GII.4, the latter of which is now the leading cause of outbreaks in the United States.

Norovirus can spread from person to person through infected food or water or contaminated surfaces. The best prevention is proper hand washing, but the virus is so contagious that people can become ill even from contact with viral particles in the air. Not everyone who is exposed to norovirus becomes infected and of those who are infected, not everyone gets sick, said Dr. Bernstein. But it nonetheless is very common, and can be serious, particularly for children and older adults.

"If the vaccine continues to prove as effective as our initial results indicate, it could be used for specific populations or situations – in those at a higher risk of severe disease such as the elderly or at high risk for infection or transmission such as in day care, people going on a cruise, those in or in the military," said Dr. Bernstein. "Or it could be offered to everyone, since all of us are exposed at one time or another."

AT A GLANCE

  • An investigational vaccine reduces symptoms of norovirus gastrointestinal (GI) infection by 52 percent, an early study shows.
  • Norovirus is the most common cause of GI illness, sickening one in 15 Americans every year, and killing as many as 800.
  • In the randomized multicenter study, people drank water infected with the virus. Those who had been vaccinated experienced a 52 percent reduction in vomiting and/or diarrhea versus those who did not receive the vaccine.
  • If further testing proves the effective, it might be offered to the general population, or people most likely to be exposed to , such as those in the military, who are going on cruises, or who live in nursing homes.

Related Stories

Monoclonal antibody effective against norovirus

Jul 24, 2013

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one ...

Vaccine against epidemic gastroenteritis being tested

Dec 09, 2011

(Medical Xpress) -- A new vaccine is being tested in the US that may protect against the norovirus, which causes "stomach flu" or acute viral gastroenteritis, that can occur in confined living settings such as cruise ships, ...

Research shows copper destroys norovirus

May 28, 2013

New research from the University of Southampton shows that copper and copper alloys will rapidly destroy norovirus - the highly-infectious sickness bug. The virus can be contracted from contaminated food ...

Recommended for you

Obama addresses West Africans on facts about Ebola

9 hours ago

President Barack Obama urged West Africans on Tuesday to wear gloves and masks when caring for Ebola patients or burying anyone who died of the disease. He also discouraged the traditional burial practice ...

Gluten-free diet benefits asymptomatic EmA+ adults

10 hours ago

(HealthDay)—Asymptomatic individuals with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD), according to a study published in the September issue of Gastroenterology.

Another US health worker infected with Ebola

10 hours ago

A third American health worker has tested positive for the Ebola virus while working with patients in West Africa, the Christian missionary group SIM said Tuesday.

UN implores all countries to help on Ebola

12 hours ago

The international group Doctor Without Borders warned Tuesday that the world is 'losing the battle' against Ebola, while U.N. officials implored all countries to quickly step up their response by contributing health experts ...

Travel restrictions could worsen Ebola crisis: experts

16 hours ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

User comments